ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Georgia » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Georgia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
HEMACHANDRAN NAIR M.D.

Cardiovascular Disease

25,759

$1.25M

918
736 are 65+

6%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$49
Average prescription price

Avg: $56

MANUEL VEGA MD, FACC, FSCAI

Cardiovascular Disease

24,006

$910K

1359
943 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 25%

$38
Average prescription price

Avg: $56

DANNIS HOOD MD

Cardiovascular Disease

22,185

$1.2M

934
728 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$54
Average prescription price

Avg: $56

MOHAMMAD MASROOR M.D.

Cardiovascular Disease

17,963

$1.13M

523
471 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$63
Average prescription price

Avg: $56

SUBODH AGRAWAL MD

Cardiovascular Disease

17,225

$900K

1349
970 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$52
Average prescription price

Avg: $56

CHARLIE ROUSE M.D.

Cardiovascular Disease

16,319

$785K

1072
830 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$48
Average prescription price

Avg: $56

MAC BOWMAN MD

Cardiovascular Disease

15,514

$936K

1106
901 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 25%

$60
Average prescription price

Avg: $56

MARSHA CERTAIN M.D.

Cardiovascular Disease

15,231

$703K

732
652 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$46
Average prescription price

Avg: $56

NARASIMHULU NEELAGARU M.D.

Cardiovascular Disease

14,093

$540K

574
471 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 25%

$38
Average prescription price

Avg: $56

LAURENCE LESSER MD

Cardiovascular Disease

13,854

$911K

1174
1056 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$66
Average prescription price

Avg: $56

MITCHELL JONES M.D.

Cardiovascular Disease

13,795

$615K

768
666 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$45
Average prescription price

Avg: $56

D REMINGTON M.D.

Cardiovascular Disease

13,700

$599K

860
747 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$44
Average prescription price

Avg: $56

RAJIV VERMA M.D.

Cardiovascular Disease

11,774

$534K

569
438 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$45
Average prescription price

Avg: $56

HOMAYOUN AMIN M.D.

Cardiovascular Disease

11,761

$619K

935
759 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 25%

$53
Average prescription price

Avg: $56

CHARLES PETTUS MD

Cardiovascular Disease

11,734

$638K

944
884 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$54
Average prescription price

Avg: $56

STANLEY SHIN MD

Cardiovascular Disease

11,213

$407K

736
569 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 25%

$36
Average prescription price

Avg: $56

AMY KINGMAN M.D.

Cardiovascular Disease

11,170

$714K

932
763 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 25%

$64
Average prescription price

Avg: $56

KAREN HANNA M.D.

Cardiovascular Disease

10,909

$474K

660
558 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$43
Average prescription price

Avg: $56

AVERY STRICKLAND M.D.

Cardiovascular Disease

10,491

$483K

507
452 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$46
Average prescription price

Avg: $56

YITZCHAK HERMONI M.D.

Cardiovascular Disease

10,215

$576K

705
636 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $56

PAUL MURRAY MD

Cardiovascular Disease

10,111

$529K

734
608 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$52
Average prescription price

Avg: $56

NARESH PARIKH M.D.

Cardiovascular Disease

10,059

$604K

762
600 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 25%

$60
Average prescription price

Avg: $56

EZAD AHMAD M.D.

Cardiovascular Disease

9,830

$616K

743
565 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 25%

$63
Average prescription price

Avg: $56

NASSER TEHRANI MD

Cardiovascular Disease

9,798

$600K

780
503 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 25%

$61
Average prescription price

Avg: $56

GEORGE MYERS MD

Cardiovascular Disease

9,765

$344K

982
767 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 25%

$35
Average prescription price

Avg: $56

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank